Superworth

Merck EPS MRK

Diluted earnings per share by quarter and over the last twelve months, from 2008.

Last 12 months, to Sep 30, 2026
$0.97
Latest quarter, Q3 FY26
$2.04
−12% on a year earlier
Fiscal year 2025
$7.28
+8% on the year before

Merck's earnings per share was $0.97 over the twelve months to Sep 30, 2026, down 87% on a year earlier.

In its latest quarter, Q3 FY26, it was $2.04, down 12% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 21% a year on average.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$7.28+8%
FY2024$6.73+4707%
FY2023$0.14−98%
FY2022$5.71+11%
FY2021$5.14+86%
FY2020$2.77−27%
FY2019$3.81+64%
FY2018$2.32+170%
FY2017$0.86−38%
FY2016$1.39−11%
FY2015$1.56−62%
FY2014$4.10+181%
FY2013$1.46−27%
FY2012$2.00−1%
FY2011$2.03+652%

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26$2.04−12%$0.97
Q2 FY26−$0.54−131%$1.25
Q1 FY26−$1.72−186%$3.55
Q4 FY25$1.19−20%$7.28
Q3 FY25$2.32+87%$7.57
Q2 FY25$1.76−18%$6.49
Q1 FY25$2.01+7%$6.87
Q4 FY24$1.48n/a$6.73
Q3 FY24$1.24−33%$4.77
Q2 FY24$2.14n/a$5.39
Q1 FY24$1.87+68%$0.90
Q4 FY23−$0.48−141%$0.14

Against its peers

Companies in Drug Manufacturers - General nearest Merck's size, closest first, today.

CompanyEPS, 12 monthsGrowth
MRKMerck$0.97−87% a year
ABBVAbbVie$5.81+340% a year
AMGNAmgen$16.09+32% a year
GILDGilead Sciences−$3.16−149% a year
JNJJohnson & Johnson$6.60−36% a year
PFEPfizer$0.76−60% a year
BMYBristol-Myers Squibb$4.51+52% a year
LLYEli Lilly and$30.81+51% a year
BIIBBiogen$5.65−46% a year
Peer median$5.73

Where Merck ranks

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Merck

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.